StockNews.AI
TVGN
StockNews.AI
193 days

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology's Potential as a Scalable Medical Countermeasure

1. Tevogen Bio discussed ExacTcell with BARDA, showcasing its viral countermeasure potential. 2. Positive proof-of-concept trial results for TVGN 489 enhance investor confidence. 3. ExacTcell technology may improve public health response capability against viral threats. 4. Tevogen's AI integration in development may streamline production and efficacy. 5. Strong intellectual property portfolio supports Tevogen's market position.

4m saved
Insight
Article

FAQ

Why Bullish?

The engagement with BARDA signifies potential future partnerships, similar to past biotech successes.

How important is it?

The discussion with a federal authority opens paths for funding and support, crucial for biotech growth.

Why Long Term?

Developments in immunotherapy can take time; past breakthroughs gained value after multiple years.

Related Companies

BARDAVITALDOD
WARREN, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, met the Center for the Biomedical Advanced Research and Development Authority (BARDA) TechWatch team. The discussion focused on Tevogen Bio’s affordable and scalable ExacTcell technology, the positive results of its proof-of-concept (POC) clinical trial for TVGN 489, the use of Artificial Intelligence in its process and future manufacturing capabilities. During the meeting, Tevogen Bio discussed ExacTcell’s unique ability to rapidly adapt to emerging viral threats, positioning it as a potential countermeasure to safeguard public health. Tevogen Bio will follow up with key federal entities and continue to update stakeholders. VITAL Biotech Accelerator ProgramDepartment of Defense - Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear DefenseAntivirals and Antitoxins Branch within BARDA’s Division of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701 Communications@Tevogen.com A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d566f0b7-923e-490e-b13f-50284c886cd7 Tevogen Bio's ExacTcell Technology: MoA and Development An overview of the ExacTcell technology Mechanism of Action and Development.

Related News